[Effects of all trans retinoic acid on the expression alterations of beta-protein 1 in human breast cancer cell lines of MDA-MB-468 and MCF-7].
To explore the effects of all trans retinoic acid (ATRA) on the cell proliferation and expression alterations of beta-protein 1 (BP1) in human breast cancer cells lines of MDA-MB-468 and MCF-7. The proliferation changes were detected by thiazolyl blue tetrazolium bromide (MTT) after the treatment of ATRA. At the dose of 10(-5) mol/L ATRA, the expression of BP1 was measured by reverse transcription-polymerase chain reaction (RT-PCR) and immunochemistry. After the treatment of ATRA, the proliferation of cells and the expression of BP1 decreased. Optical density ratio (ODR) of each group decreased from 0.85 ± 0.01, 0.71 ± 0.01 to 0.75 ± 0.02, 0.72 ± 0.06 at 24 h, 0.55 ± 0.01, 0.52 ± 0.05 at 48 h and 0.34 ± 0.02, 0.48 ± 0.03 at 72 h. Significant differences existed among different time groups (P < 0.01). The mean optical density (MOD) of each group decreased from 0.509 ± 0.081, 0.826 ± 0.015 to 0.509 ± 0.081, 0.826 ± 0.015 at 24 h, 0.270 ± 0.022, 0.641 ± 0.041 at 48 h and 0.145 ± 0.019 and 0.206 ± 0.179 at 72 h. Significant differences existed among different time groups (P < 0.01). ATRA can inhibit the proliferation and the expression of BP1 in breast cancer cells. And BP1 gene may become a therapeutic target for the ATRA-mediated inhibited growth of breast cancer cells.